

Issued by JPAC: 16 March 2022

Implementation: To be determined by each Service

Change Notification UK National Blood Services No. 14 - 2022

Psoriasis

This change applies to all the Tissue and Cell Donor Selection Guidelines

Psoriasis Entry in the Bone Marrow & Peripheral Blood Stem Cell Donor Selection Guidelines

Please amend the following sections of this entry:

<i>Obligatory</i>	<p>Must not donate if:</p> <p>a) Has ever taken Etretinate (Tigason).</p> <p>b) Less than 24 months from the last dose of Acitretin (Neotigason).</p> <p>a e) Generalized or severe.</p> <p>b) d) Associated with arthropathy.</p> <p>c) e) There is secondary infection.</p> <p>d) Immunosuppressed</p>
<i>Discretionary:</i>	<p>a) If mild, the venepuncture/harvest site is unaffected and only using topical treatment, accept.</p> <p>b) If the donor is on immunosuppressive medication, see Immunosuppression entry</p>
<i>See:</i>	<p>Autoimmune Disease Immunosuppression</p>
<i>Reason for Change:</i>	<p>There has been an increase in the deferral period after using acitretin (Neotigason®) from 12 to 24 months.</p> <p>Treatment with Etretinate/Neotigason is no longer a reason for deferral. Link to 'immunosuppression' entry added</p>

Psoriasis Entry in the Cord Blood Donor Selection Guidelines

Please amend the following sections of this entry:

<i>Obligatory</i>	<p>Must not donate if:</p> <p>a) Has ever taken Etretnate (Tigason).</p> <p>b) Less than 24 months from the last dose of Acitretin (Neotigason).</p> <p>a e) Generalized or severe.</p> <p>d) Associated with arthropathy.</p> <p>b) e) There is secondary infection.</p> <p>c) Immunosuppressed</p>
<i>Discretionary:</i>	<p>a) If mild and only using topical treatment, accept.</p> <p>b) If the donor is on immunosuppressive medication, see Immunosuppression entry</p>
<i>Additional Information:</i>	<p>Psoriasis is primarily a skin condition caused by an autoimmune process. About one in ten people with psoriasis may develop joint problems (psoriatic arthropathy). Sometimes the disease is treated with powerful drugs to suppress the underlying autoimmune process. This may alter the body's defence mechanisms to infection. In such cases, donations should not be taken.</p>
<i>See:</i>	<p>Autoimmune Disease Immunosuppression</p>
<i>Reason for Change:</i>	<p>There has been an increase in the deferral period after using acitretin (Neotigason®) from 12 to 24 months.</p> <p>Treatment with Etretnate/Neotigason is no longer a reason for deferral. To clarify that if there is no involvement of the tissue to be donated, donation may proceed.</p>

Psoriasis Entry in the Living Tissue Donor Selection Guidelines

Please amend the following sections of this entry:

<i>Obligatory</i>	<p>Must not donate if:</p> <p>a) Has ever taken Etretnate (Tigason).</p> <p>b) Less than 24 months from the last dose of Acitretin (Neotigason).</p> <p>a e) Generalized or severe.</p> <p>b) d) Associated with arthropathy.</p>
-------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

	<p>c) e) There is secondary infection.</p> <p>d) Immunosuppressed</p>
<i>Discretionary:</i>	<p>a) If the quality of the tissue being donated is not affected, accept</p> <p>b) If mild and only using topical treatment, accept.</p> <p>c) If the donor is on immunosuppressive medication, see Immunosuppression entry</p>
<i>Additional Information:</i>	<p>Psoriasis is primarily a skin condition caused by an autoimmune process. About one in ten people with psoriasis may develop joint problems (psoriatic arthropathy). Sometimes the disease is treated with powerful drugs to suppress the underlying autoimmune process. This may alter the body's defence mechanisms to infection. In such cases, donations should not be taken. Donations may be accepted if the safety and quality of the tissues is not affected.</p>
<i>See:</i>	<p>Autoimmune Disease Immunosuppression</p>
<i>Reason for Change:</i>	<p>There has been an increase in the deferral period after using acitretin (Neotigason®) from 12 to 24 months.</p> <p>Treatment with Etretnate/Neotigason is no longer a reason for deferral. To clarify that if there is no involvement of the tissue to be donated, donation may proceed. Link to 'immunosuppression' entry added</p>

Psoriasis Entry in the Deceased Tissue Donor Selection Guidelines

Please amend the following sections of this entry:

<i>Obligatory</i>	<p>Must not donate if:</p> <p>a) Has ever taken Etretnate (Tigason).</p> <p>b) Less than 24 months from the last dose of Acitretin (Neotigason).</p> <p>a) e) Generalized or severe.</p> <p>d) Associated with arthropathy.</p> <p>b) e) There is secondary infection.</p> <p>c) Immunosuppressed</p>
<i>Discretionary:</i>	<p>1. All tissues:</p> <p>a) If the quality of the tissue being donated is not affected, accept</p> <p>b) If mild and only using topical treatment, accept.</p>

	<p>c) If the donor is on immunosuppressive medication, see Immunosuppression entry</p> <p>2- Eyes: If no ocular involvement, accept even if treated with Etretnate (Tigason) or Acitretin (Neotigason).</p>
<i>Additional Information:</i>	<p>Psoriasis is primarily a skin condition caused by an autoimmune process. About one in ten people with psoriasis may develop joint problems (psoriatic arthropathy). Sometimes the disease is treated with powerful drugs to suppress the underlying autoimmune process. This may alter the body's defence mechanisms to infection. In such cases, donations should not be taken. Donations may be accepted if the safety and quality of the tissues is not affected.</p>
<i>See:</i>	<p>Autoimmune Disease Immunosuppression</p>
<i>Reason for Change:</i>	<p>There has been an increase in the deferral period after using acitretin (Neotigason®) from 12 to 24 months.</p> <p>Treatment with Etretnate/Neotigason is no longer a reason for deferral. To clarify that if there is no involvement of the tissue to be donated, donation may proceed. Link to 'immunosuppression' entry added.</p>

Sheila MacLennan

Dr Sheila MacLennan
Professional Director - Joint UKBTS Professional Advisory Committee
☎ Direct Dial : (0113) 820 8638 ✉ sheila.maclennan@nhsbt.nhs.uk